A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
This study is being conducted to evaluate the safety and efficacy of treatment with CTP-499
for 24 weeks in patients with chronic kidney disease, Type 2 diabetic nephropathy and who are
currently receiving treatment with an angiotensin converting enzyme inhibitor (ACEI) and/or
angiotensin II receptor blocker (ARB).